2016 American Transplant Congress
Patients Treated with Belatacept Show Low Levels of APRIL and HLA Antibodies.
Belatacept, a fusión protein that blocks the B7-CD28 costimulation pathway, decreases the level of antibodies in non-human primates and murine models but, few studies have…2016 American Transplant Congress
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.
Introduction Transplant glomerulopathy (TG) is commonly associated with chronic antibody mediated rejection and is a major cause of late kidney allograft loss with no established…2016 American Transplant Congress
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
1Pathology, Emory University, Atlanta, GA; 2Emory Transplant Center, Emory University, Atlanta, GA.
AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…2016 American Transplant Congress
Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies.
INTRODUCTION: Nephrosclerosis is often associated with pathological injury to kidneys resulting from chronic high blood pressure and/or aging, and may predict the progression of decline…2016 American Transplant Congress
An Assurance of Insurance: Should Living Kidney Donors Be Required to Have Health Insurance?
Lack of health insurance has been related lack of access to health care, poorer health, and increased mortality. In this study, we investigate sociodemographic predictors…2016 American Transplant Congress
Deceased Donor ABO-Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity.
Introduction: Patients with blood group O or B wait significantly longer for a kidney transplant than other groups. Blood group incompatible transplantation is widely accepted…2016 American Transplant Congress
Early Hospital Readmisison Among Older Kideny Transplant Recipients.
Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.
BACKGROUND: We previously established 31% of all kidney transplant (KT) recipients experience early hospital readmission (EHR). We hypothesized that rates of EHR might be higher…2016 American Transplant Congress
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
1IU Health, University Hospital, Indianapolis, IN; 2Butler University, Indianapolis, IN.
Valganciclovir is the preferred prophylactic therapy for the prevention of CMV in transplant recipients and is the most expensive medication required post transplantation. The objective…2016 American Transplant Congress
The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.
Study purpose: ABMR is a driving force of long-term allograft loss in organ transplantation. The present study was designed to characterize the phenotypic diversity of…2016 American Transplant Congress
Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.
Columbia University, New York.
INTRO: Progress in AMR treatment has improved early graft survival. Since the new kidney allocation system results in more sensitized patients getting transplanted, we expect…
- « Previous Page
- 1
- …
- 424
- 425
- 426
- 427
- 428
- …
- 531
- Next Page »